WO2012103496A3 - Expression of soluble viral fusion glycoproteins in mammalian cells - Google Patents

Expression of soluble viral fusion glycoproteins in mammalian cells Download PDF

Info

Publication number
WO2012103496A3
WO2012103496A3 PCT/US2012/022997 US2012022997W WO2012103496A3 WO 2012103496 A3 WO2012103496 A3 WO 2012103496A3 US 2012022997 W US2012022997 W US 2012022997W WO 2012103496 A3 WO2012103496 A3 WO 2012103496A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression
viral fusion
mammalian cells
fusion glycoproteins
glycoproteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/022997
Other languages
French (fr)
Other versions
WO2012103496A2 (en
Inventor
Roderick Tang
Gregory M. HAYES
Heather LAWLOR
Peifeng Chen
Yi Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to CN2012800057456A priority Critical patent/CN103339140A/en
Priority to AU2012211126A priority patent/AU2012211126A1/en
Priority to CA2825722A priority patent/CA2825722A1/en
Priority to BR112013018845A priority patent/BR112013018845A2/en
Priority to EP12738750.4A priority patent/EP2668282A2/en
Priority to JP2013551388A priority patent/JP2014505477A/en
Priority to US13/980,712 priority patent/US20140024076A1/en
Publication of WO2012103496A2 publication Critical patent/WO2012103496A2/en
Publication of WO2012103496A3 publication Critical patent/WO2012103496A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The technology relates in part to production (i.e., expression) of recombinant viral fusion glycoproteins and nucleic acids that encode such viral fusion glycoproteins. In some embodiments, human respiratory syncytial virus fusion protein (RSV-F) and human parainfluenza virus 3 fusion protein (hPIV3-F) are expressed.
PCT/US2012/022997 2011-01-28 2012-01-27 Expression of soluble viral fusion glycoproteins in mammalian cells Ceased WO2012103496A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN2012800057456A CN103339140A (en) 2011-01-28 2012-01-27 Expression of soluble viral fusion glycoproteins in mammalian cells
AU2012211126A AU2012211126A1 (en) 2011-01-28 2012-01-27 Expression of soluble viral fusion glycoproteins in mammalian cells
CA2825722A CA2825722A1 (en) 2011-01-28 2012-01-27 Expression of soluble viral fusion glycoproteins in mammalian cells
BR112013018845A BR112013018845A2 (en) 2011-01-28 2012-01-27 expression of mammalian cell soluble viral fusion glycoproteins
EP12738750.4A EP2668282A2 (en) 2011-01-28 2012-01-27 Expression of soluble viral fusion glycoproteins in mammalian cells
JP2013551388A JP2014505477A (en) 2011-01-28 2012-01-27 Expression of soluble viral fusion glycoproteins in mammalian cells
US13/980,712 US20140024076A1 (en) 2011-01-28 2012-01-27 Expression Of Soluble Viral Fusion Glycoproteins In Mammalian Cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437531P 2011-01-28 2011-01-28
US61/437,531 2011-01-28

Publications (2)

Publication Number Publication Date
WO2012103496A2 WO2012103496A2 (en) 2012-08-02
WO2012103496A3 true WO2012103496A3 (en) 2013-03-21

Family

ID=46581434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/022997 Ceased WO2012103496A2 (en) 2011-01-28 2012-01-27 Expression of soluble viral fusion glycoproteins in mammalian cells

Country Status (8)

Country Link
US (1) US20140024076A1 (en)
EP (1) EP2668282A2 (en)
JP (1) JP2014505477A (en)
CN (1) CN103339140A (en)
AU (1) AU2012211126A1 (en)
BR (1) BR112013018845A2 (en)
CA (1) CA2825722A1 (en)
WO (1) WO2012103496A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968518A4 (en) * 2013-03-15 2016-08-24 Vlp Biotech Inc Palivizumab epitope-based virus-like particles
MD3718565T2 (en) 2015-10-22 2022-09-30 Modernatx Inc Respiratory virus vaccines
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUS
CN106754677A (en) * 2016-12-24 2017-05-31 严志海 A kind of external mesenchymal stem cells MSCs culture medium
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
KR102700187B1 (en) * 2017-09-29 2024-08-28 에스케이바이오사이언스(주) Modified soluble RSV F protein antigen
WO2019066437A1 (en) * 2017-09-29 2019-04-04 에스케이바이오사이언스 주식회사 Soluble modified respiratory syncytial virus (rsv) f protein antigen
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
EP3696189A1 (en) * 2019-02-14 2020-08-19 European Molecular Biology Laboratory Means and methods for preparing engineered target proteins by genetic code expansion in a target protein selective manner
CN113993994A (en) * 2019-03-28 2022-01-28 因特利亚治疗公司 Polynucleotides, compositions and methods for polypeptide expression
CN110894215B (en) * 2019-12-16 2021-08-27 中国农业大学 Peste des petits ruminants virus antigen and colloidal gold immunochromatographic test paper card for detecting Peste des petits ruminants virus antibody
CN115612674B (en) * 2021-07-14 2026-01-30 上海荣瑞医药科技有限公司 An oncolytic virus and its uses
CN118434756A (en) * 2021-11-19 2024-08-02 达冕生物有限公司 Compositions and methods of RNA respiratory syncytial virus (RSV) vaccines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161846A1 (en) * 2000-11-22 2004-08-19 Mason Anthony John Method of expression and agents identified thereby
WO2008114149A2 (en) * 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
WO2009128951A2 (en) * 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of respiratory synctial virus proteins and methods of use
WO2010014974A2 (en) * 2008-08-01 2010-02-04 President And Fellows Of Harvard College Phase transition devices and smart capacitive devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
DE102004037611B4 (en) * 2004-08-03 2013-10-02 Geneart Ag Inducible gene expression
CN101293098A (en) * 2007-04-28 2008-10-29 北京迪威华宇生物技术有限公司 Recombined cattle O type foot and mouth disease virus amalgamation protein vaccine
MX2012000036A (en) * 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vaccine.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161846A1 (en) * 2000-11-22 2004-08-19 Mason Anthony John Method of expression and agents identified thereby
WO2008114149A2 (en) * 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
WO2009128951A2 (en) * 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of respiratory synctial virus proteins and methods of use
WO2010014974A2 (en) * 2008-08-01 2010-02-04 President And Fellows Of Harvard College Phase transition devices and smart capacitive devices

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUANG ET AL.: "Recombinant respiratory syncytial virus F protein expression is hindered by inefficient nuclear export and mRNA processing.", VIRUS GENES, vol. 40, 2010, pages 212 - 221, XP019775273 *

Also Published As

Publication number Publication date
BR112013018845A2 (en) 2016-07-19
AU2012211126A1 (en) 2013-07-18
US20140024076A1 (en) 2014-01-23
EP2668282A2 (en) 2013-12-04
WO2012103496A2 (en) 2012-08-02
CA2825722A1 (en) 2012-08-02
JP2014505477A (en) 2014-03-06
CN103339140A (en) 2013-10-02

Similar Documents

Publication Publication Date Title
Swiecki et al. Type I interferons: diversity of sources, production pathways and effects on immune responses
WO2016118642A8 (en) Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
BR112015013525A2 (en) a method for producing a fusion protein as well as a composition comprising a fusion protein
TR201900213T4 (en) Method of production of a polypeptide or related virus in a continuous cell culture.
WO2013093760A3 (en) Compositions, methods, and kits for preparing sialylated recombinant proteins
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
WO2012068317A3 (en) Methods for producing recombinant proteins
WO2015016761A8 (en) Mscs in the treatment of inflammatory pulmonary diseases
WO2012140127A3 (en) Method for priming of t cells
IN2012DN03209A (en)
WO2012031263A3 (en) Cell culture system for bioreactor scale-up of cells
CA2877521C (en) Cells for producing recombinant iduronate-2-sulfatase
MX2012000036A (en) Vaccine.
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
BR112015011389A2 (en) RESPIRATORY SYNCYTIAL VIRUS F COMPLEX, METHODS FOR PRODUCING A RESPIRATORY SYNCYCIAL VIRUS F COMPLEX AND FOR INDUCING AN IMMUNOLOGICAL RESPONSE TO AN RSV F IN AN INDIVIDUAL, AND, IMMUNOGENIC COMPOSITION
WO2012145759A3 (en) Methods of protein production and compositions thereof
NZ612603A (en) Virus like particle production in plants
WO2012098537A8 (en) Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
BR112014015933A2 (en) methods and materials to reduce recombinant protein degradation
WO2010088565A8 (en) Nucleic acid delivery using modified chitosans
HRP20200941T1 (en) Pharmaceutical preparation comprising recombinant hcg
HK1209790A1 (en) Method of producing recombinant iduronate-2-sulfatase
BR112013018845A2 (en) expression of mammalian cell soluble viral fusion glycoproteins
WO2011152694A8 (en) Fusion protein having factor vii activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12738750

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2012211126

Country of ref document: AU

Date of ref document: 20120127

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2825722

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013551388

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2012738750

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012738750

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13980712

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013018845

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013018845

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130723